95 related articles for article (PubMed ID: 1980915)
1. Expression of the multidrug resistance gene in human tumors.
Kim R
Hiroshima J Med Sci; 1990 Sep; 39(3):71-7. PubMed ID: 1980915
[TBL] [Abstract][Full Text] [Related]
2. Resistance to TNF-alpha and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression.
Zyad A; Bénard J; Tursz T; Clarke R; Chouaib S
Cancer Res; 1994 Feb; 54(3):825-31. PubMed ID: 7905787
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of MDR1 (multidrug resistance) gene expression by RT-PCR].
Nakashima A; Okabayashi T; Nakatani S; Kataoka M; Johira H; Takeda A; Orita K
Gan To Kagaku Ryoho; 1993 Apr; 20(6):831-3. PubMed ID: 8387754
[TBL] [Abstract][Full Text] [Related]
4. Comparison of multidrug resistance gene expression levels with malignant potentials and influence of chemotherapy in urothelial cancers.
Kakehi Y; Wu WJ; Kim WJ; Arao S; Fukumoto M; Yoshida O
Int J Urol; 1995 Nov; 2(5):309-15. PubMed ID: 8749949
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of two human doxorubicin-resistant cell lines: evidence for differing multidrug resistance mechanisms.
Slovak ML; Coccia M; Meltzer PS; Trent JM
Anticancer Res; 1991; 11(1):423-8. PubMed ID: 1673331
[TBL] [Abstract][Full Text] [Related]
6. MDR1 gene expression in primary and advanced breast cancer.
Yang X; Uziely B; Groshen S; Lukas J; Israel V; Russell C; Dunnington G; Formenti S; Muggia F; Press MF
Lab Invest; 1999 Mar; 79(3):271-80. PubMed ID: 10092063
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance gene and P-glycoprotein expression in anaplastic carcinoma of the thyroid.
Yamashita T; Watanabe M; Onodera M; Shimaoka K; Ito K; Fujimoto Y; Itoyama S; Sugawara I
Cancer Detect Prev; 1994; 18(5):407-13. PubMed ID: 7812988
[TBL] [Abstract][Full Text] [Related]
8. Factors contributing to adriamycin sensitivity in human xenograft tumors: the relationship between expression of the MDR1, GST-pi and topoisomerase II genes and tumor sensitivity to adriamycin.
Kim R; Hirabayashi N; Nishiyama M; Jinushi K; Toge T; Okada K
Anticancer Res; 1992; 12(1):241-5. PubMed ID: 1314532
[TBL] [Abstract][Full Text] [Related]
9. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
10. Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells.
Li B; Ye T; Zhao L; Li DH; Gou XH; Zhao LY; Han L; Chen L; Yan LN; Gong JP
Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):552-9. PubMed ID: 17085341
[TBL] [Abstract][Full Text] [Related]
11. Study of multidrug resistance (mdr1) gene in non-small-cell lung cancer.
Shin HJ; Lee JS; Hong WK; Shin DM
Anticancer Res; 1992; 12(2):367-70. PubMed ID: 1374598
[TBL] [Abstract][Full Text] [Related]
12. Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer.
Arao S; Suwa H; Mandai M; Tashiro H; Miyazaki K; Okamura H; Nomura H; Hiai H; Fukumoto M
Cancer Res; 1994 Mar; 54(5):1355-9. PubMed ID: 7509719
[TBL] [Abstract][Full Text] [Related]
13. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP
Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927
[TBL] [Abstract][Full Text] [Related]
14. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
15. Expression of a human multidrug resistance gene in ovarian carcinomas.
Bourhis J; Goldstein LJ; Riou G; Pastan I; Gottesman MM; Bénard J
Cancer Res; 1989 Sep; 49(18):5062-5. PubMed ID: 2766278
[TBL] [Abstract][Full Text] [Related]
16. Expression of MDR1, GST-pi and topoisomerase II as an indicator of clinical response to adriamycin.
Kim R; Hirabayashi N; Nishiyama M; Saeki S; Toge T; Okada K
Anticancer Res; 1991; 11(1):429-31. PubMed ID: 1850221
[TBL] [Abstract][Full Text] [Related]
17. Genes amplified and overexpressed in human multidrug-resistant cell lines.
Van der Bliek AM; Baas F; Van der Velde-Koerts T; Biedler JL; Meyers MB; Ozols RF; Hamilton TC; Joenje H; Borst P
Cancer Res; 1988 Nov; 48(21):5927-32. PubMed ID: 2901906
[TBL] [Abstract][Full Text] [Related]
18. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
[TBL] [Abstract][Full Text] [Related]
19. Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer.
Punyammalee B; Manoromana S; Purisa W; Chariyalertsak S; Rerkamnuaychok B
J Med Assoc Thai; 1997 Sep; 80 Suppl 1():S162-73. PubMed ID: 9347665
[TBL] [Abstract][Full Text] [Related]
20. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
Ramachandran C; Wellham LL
Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
